News headlines about Agenus (NASDAQ:AGEN) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Agenus earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 48.0551500344592 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news stories that may have effected Accern’s analysis:
- Short Interest in Agenus Inc. (AGEN) Expands By 21.5% (americanbankingnews.com)
- Agenus Inc. Expected to Post FY2017 Earnings of ($1.25) Per Share (AGEN) (americanbankingnews.com)
- Agenus To Present on Lead Antibody Programs AGEN1884 (CTLA … – PR Newswire (press release) (prnewswire.com)
- Agenus Inc. (NASDAQ:AGEN) Unchanged As Q3 Earnings Meet Estimates – Stock News Union (blog) (stocknewsunion.com)
- Agenus To Present on Lead Antibody Programs AGEN1884 (CTLA-4) and AGEN2034 (PD-1) at SITC 2017 (finance.yahoo.com)
Agenus (NASDAQ:AGEN) traded up $0.18 during trading hours on Monday, reaching $3.73. The company’s stock had a trading volume of 1,596,100 shares, compared to its average volume of 1,207,128. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of -2.39. Agenus has a twelve month low of $3.20 and a twelve month high of $5.91.
Agenus (NASDAQ:AGEN) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.37). The firm had revenue of $3.40 million during the quarter, compared to the consensus estimate of $5.91 million. The firm’s revenue for the quarter was down 24.4% compared to the same quarter last year. analysts predict that Agenus will post -1.19 earnings per share for the current fiscal year.
A number of equities analysts recently commented on AGEN shares. BidaskClub cut Agenus from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. ValuEngine raised Agenus from a “strong sell” rating to a “sell” rating in a report on Monday, July 24th. Jefferies Group LLC reissued a “buy” rating and set a $7.00 price target on shares of Agenus in a report on Friday, August 4th. Finally, Zacks Investment Research raised Agenus from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a report on Wednesday, October 25th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $5.81.
In other news, CEO Garo H. Armen bought 100,000 shares of Agenus stock in a transaction dated Monday, October 30th. The shares were purchased at an average cost of $3.55 per share, with a total value of $355,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 7.90% of the company’s stock.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.